Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 4
2006 pubmed

[Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers.

Barnetson. Ross StC RS; Ooi. Terry K T TK; Zhuang. Liqing L; Halliday. Gary M GM; Reid. Catherine M CM; Walker. Patrick C PC; Humphrey. Stuart M SM; Kleinig. Michael J MJ

Key Findings

  • Melanotan‑I increased skin melanin significantly, especially in low‑baseline melanin individuals (≈41% rise).
  • In low‑MED (burn‑prone) skin, sunburn cell formation after high UV exposure dropped >50% after treatment.
  • Thymine‑dimer DNA damage in the epidermis fell by 59% after melanotan‑I administration.

Practical Outcomes

  • For biohackers, melanotan‑I can be used as a sub‑cutaneous protocol (0.16 mg/kg, three 10‑day cycles) to enhance tanning and potentially lower UV‑induced skin damage. Expect the biggest pigment boost if you start with very light skin. Monitor for side effects and remember this is still early‑stage research, not an approved sunscreen substitute.

Summary

A study gave a synthetic hormone called melanotan‑I (0.16 mg per kg body weight, injected under the skin in three 10‑day rounds over three months) to fair‑skinned volunteers. It made their skin much darker, especially in people who started with very little melanin, and cut sunburn cell damage by more than half and DNA damage by about 60%. This suggests melanotan‑I can boost natural tanning and give real UV protection, but it’s still an experimental approach.

Abstract

Epidermal melanin reduces some effects of UV radiation, the major cause of skin cancer. To examine whether induced melanin can provide protection from sunburn injury, 65 subjects completed a trial with the potent synthetic melanotropin, [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone ([Nle4-D-Phe7]-alpha-MSH) delivered by subcutaneous injection into the abdomen at 0.16 mg/kg for three 10-day cycles over 3 months. Melanin density, measured by reflectance spectroscopy, increased significantly in all [Nle4-D-Phe7]-alpha-MSH-treated subjects. The highest increases were in volunteers with lowest baseline skin melanin levels. In subjects with low minimal erythemal dose (MED) skin type, melanin increased by an average of 41% (from 2.55 to 3.59, P < 0.0001 vs placebo) over eight separate skin sites compared with only 12% (from 4.18 to 4.70, P < 0.0001 vs placebo) in subjects with a high-MED skin type. Epidermal sunburn cells resulting from exposure to 3 MED of UV radiation were reduced by more than 50% after [Nle4-D-Phe7]-alpha-MSH treatment in the volunteers with low baseline MED. Thymine dimer formation was also shown to be reduced by 59% (P = 0.002) in the epidermal basal layer. This study has shown for the first time the potential ability of a synthetic hormone that augments melanin production to provide photoprotection to people who normally burn in direct sunlight.

Study Information

Provider

pubmed

Year

2006

Date

2006-06-08T00:00:00.000Z

DOI

10.1038/sj.jid.5700317